Oxford BioDynamics to expand strategic focus beyond biomarker discovery to development and commercialization of laboratory tests
Innovation Saving Lives
We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch®, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.
Our Publications on EpiSwitch®
Epigenetic footprints for neurodegenerative and autoimmune conditions: a comparative analysis.
Hunter, E, et. al.,
The Lancet Neurology Conference
October 21, 2016
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-footprints-for-neurodegenerative-and-autoimmune-conditions.pdf
Epigenetic signatures and early detection of neurodegenerative diseases.
Salter, M., et. al.,
The Lancet Neurology Conference
October 19, 2016
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/2016-LNC-Epigenetic-signatures-and-early-detection-of-neurodegenerative-diseases.pdf
Chromosome conformation capture to discover candidate epigenetic markers of Multiple Sclerosis disease severity.
Sangurdekar, D., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
September 15, 2016
http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146797/tatiana.plavina.chromosome.conformation.capture.to.discover.candidate.html?f=m3
Epigenetic profile of chromosome conformation signatures underlying multiple sclerosis and its severity.
Joesph, JP., et. al.,
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
September 14, 2016
http://onlinelibrary.ectrims-congress.eu/ectrims/2016/32nd/146441/joyce.joseph.epigenetic.profile.of.chromosome.conformation.signatures.html?f=m3
Systemic Epigenetic Biomarkers for ALS Improve Early Diagnosis, Treatment and Trials.
Jeznach, M.
International Pharmaceutical Industry
April 20, 2016
https://issuu.com/mark123/docs/ipi_march2016_web/45
Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients.
Carini, C., et. al.,
Annual Meeting of the American College of Rheumatology
November 7, 2015
http://acrabstracts.org/abstract/epigenetic-chromosome-conformations-predict-mtx-responsiveness-in-early-rheumatoid-arthritis-patients/
Development of Epigenetic Profiling of ALS Patients with Chromosome Conformation Biomarkers Offers Novel Signatures for Non-invasive Diagnostic and Prognostic Stratifications.
Hunter, E., et. al.,
14th Annual Northeast Amyotrophic Lateral Sclerosis Consortium
November 3, 2015
http://www.oxfordbiodynamics.com/wp-content/uploads/2016/10/ALSNEALS2015.pdf
A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.
Jakub, JW., et. al.,
Melanoma Research
October 3, 2015
https://www.ncbi.nlm.nih.gov/pubmed/26225582
Chromatin barcodes as biomarkers for melanoma.
Bastonini, E., et. al.,
Pigment Cell Melanoma Research
September 3, 2014
https://www.ncbi.nlm.nih.gov/pubmed/24807349
A blood-based epigenetic test for early detection of hepatocellular carcinoma (HCC).
Lim, EH., et. al.,
J Clinical Oncology
May 30, 2014
http://meetinglibrary.asco.org/content/133682-144